April 19, 2016 — Sanofi-Aventis has been hit with a federal lawsuit in California by a woman who was diagnosed with permanent hair loss (alopecia) after undergoing chemotherapy with Taxotere.
The lawsuit (PDF) was filed on March 14 by plaintiff Ami Dodson in the U.S. District Court for the Northern District of California (Case No. 4:16-cv-01251).
The victim was diagnosed with breast cancer (ductal carcinoma) in March 2010 and underwent a partial mastectomy. During a meeting to discuss further treatment, she was never informed of the risk of permanent alopecia from Taxotere.
Dodson was diagnosed with permanent hair loss after undergoing chemotherapy that included Taxotere. She says she would have considered other treatments if she had known about the risk. According to the complaint:
“Defendants [preyed] on one of the most vulnerable groups of individuals at the most difficult time in their lives. Defendants obtained billions of dollars in increased revenues at the expense of unwary cancer victims simply hoping to survive their condition and return to a normal life.”
In the United States, the label on Taxotere was updated to include permanent alopecia in December 2015. Warning labels in Europe and Canada were updated in 2012 and 2005, respectively. It is not clear why the drug-maker waited over a decade to provide warnings in the United States.
Sanofi-Aventis is facing a growing number of lawsuits accusing the drug-maker of inadequately warning about the risk of permanent baldness. Before the label updates, the drug-maker reassured women that “hair generally grows back” after treatment.
Plaintiffs say Sanofi-Aventis should have provided stronger warnings because their own studies estimated that 9.2% of breast cancer patients on Taxotere, Adriamycin, and Cyclophosphamide (TAC) experienced hair loss that persisted during a 10-year follow-up period.
Do I have a Taxotere Lawsuit?
The Schmidt Firm, PLLC is currently accepting Taxotere induced injury cases in all 50 states. If you or somebody you know has been diagnosed with permanent alopecia, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.